logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11344617 B1

PDFFull Text
Date of Patent:
May. 31, 2022

Filed:

Dec. 21, 2018

Liquid vaccines of live enveloped viruses

Applicant:

Intervet Inc., Madison, NJ (US);

Inventors:

Paul Vermeij, St. Anthonis, NL;

Edwin Kets, Heilig Landstichting, NL;

Chris Dirks, Gemert, NL;

Martin Piest, Afferden, NL;

Assignee:

Intervet Inc., Madison, NJ (US);

Attorney:

Michael D. Davis

Primary Examiner:

Shanon A Foley

Int. Cl.
CPC ...
A61K 39/155 (2006.01); C12N 7/00 (2006.01); A61K 39/12 (2006.01); A61K 9/08 (2006.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); A61K 47/10 (2017.01); A61K 39/175 (2006.01); A61K 39/215 (2006.01); A61K 39/245 (2006.01); A61K 47/22 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/155 (2013.01); A61K 9/08 (2013.01); A61K 39/12 (2013.01); A61K 39/175 (2013.01); A61K 39/215 (2013.01); A61K 39/245 (2013.01); A61K 47/10 (2013.01); A61K 47/186 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); C12N 7/00 (2013.01); A61K 2039/525 (2013.01); A61K 2039/54 (2013.01); A61K 2039/543 (2013.01); C12N 2710/16034 (2013.01); C12N 2760/00034 (2013.01); C12N 2760/18034 (2013.01); C12N 2760/18434 (2013.01); C12N 2760/18634 (2013.01); C12N 2770/20034 (2013.01);
Abstract

The present invention describes a liquid vaccine composition of a live enveloped virus and a pharmaceutically acceptable carrier, whereby the carrier is a natural deep-eutectic solvent (NADES), and the vaccine has a water activity of less than about 0.8. The NADES provides a stabilisation of the sensitive virus for prolonged time and at ambient temperature. In general, the liquid vaccine compositions according to the invention, in different compositions for the various enveloped viruses, show remarkable capabilities of stabilisation. This overcomes the need for lyophilisation, a great economic benefit. Also the liquid nature of the vaccines facilitates administration to human or animal targets.

Find Patent Forward Citations

Loading…